| 영문 | vaccine | 한글 | 백신 |
|---|---|---|---|
| 설명 | 전염병에 대하여 인공적으로 면역을 주기 위해 생체에 투여하는 항원의 하나. 병원체 및 독소에 대한 방어기구를 강화할 목적으로 사용되는 미생물제제를 말한다. 프랑스의 미생물학자 L. 파스퇴르에 의하여 제창된 용어로서, 어떤 감염증에 대하여 인공적으로 면역을 얻기 위하여 그 병원 미생물 또는 그 독소액에 적당한 조작을 가하여 만든 것을 말한다. |
||
| MMR | mass miniature radiography; masseter muscle rigidity; maternal mortality rate; measles-mumps-rubella... |
|---|---|
| MMR | 1) Measles, Mumps, Rubella; 홍역, 멈프스, 풍진 2) Mass Miniature Radiography... |
| DEV | Duck Embryo Vaccine |
| HBPV | Haemophilus influenza type B Polysaccharide(PRP) Vaccine; B형 헤모필루스 인플루엔자 피막 다당질 백신... |
| HDCV | Human Diploid Cell Vaccine; 인간 이배체 세포 백신 |
| MMR | Measles-Mumps-Rubella vaccine |
|---|---|
| MMR | MEASLES: mumps-rubella |
| MMR | Maternal mortality rates |
| MMR | Maternal mortality ratio |
| MMR | Measles, mumps and rubella |
| MMR vaccine | <drug> The mumps, measles and rubella vaccine is recommended in all infants. Typically given twice, 15 months and at 4-6 years. (27 Sep 1997) |
|---|
| MMR | Measles, mumps, rubella vaccine. (12 Dec 1998) |
|---|---|
| immunization, mmr | The standard vaccine given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most u.s. Colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination. (12 Dec 1998) |
| acellular vaccine | <immunology, pharmacology, virology> Vaccine consisting of antigenic parts of cells. (13 Nov 1997) |
| adjuvant vaccine | A vaccine that contains an adjuvant; most often the antigen (immunogen) is included in a water-in-oil emulsion (Freund incomplete type adjuvant), or is adsorbed onto an inorganic gel (alum, aluminum hydroxide or phosphate). (05 Mar 2000) |
| aqueous vaccine | A vaccine having a liquid vehicle (e.g., physiological salt solution) as distinguished from an emulsion. (05 Mar 2000) |
| attenuated vaccine | Live pathogens that have lost their virulence but are still capable of inducing a protective immune response to the virulent forms of the pathogen, e.g., Sabin polio vaccine. (05 Mar 2000) |
| autogenous vaccine | A vaccine made from a culture of the patient's own bacteria. (05 Mar 2000) |
| bacillus Calmette-Guerin vaccine | <drug> Live attenuated vaccine for tuberculosis. For groups and health care workers in high endemic areas. Not to be given to individuals with HIV infection. (15 Nov 1997) |
| BCG vaccine | <drug> Live attenuated vaccine for tuberculosis. For groups and health care workers in high endemic areas. Not to be given to individuals with HIV infection. (15 Nov 1997) |
| brucella strain 19 vaccine | A live bacterial vaccine prepared from an attenuated variant strain of Brucella abortus (strain 19); used for vaccinating cattle against brucellosis. (05 Mar 2000) |
| brucella vaccine | A bacterial vaccine for the prevention of brucellosis in man and animal. Brucella abortus vaccine is used for the immunization of cattle, sheep, and goats. (12 Dec 1998) |
| Calmette-Guerin vaccine | <drug> Live attenuated vaccine for tuberculosis. For groups and health care workers in high endemic areas. Not to be given to individuals with HIV infection. (15 Nov 1997) |
| rabies vaccine | An inactivated virus vaccine, used for preexposure immunization to persons at high risk of exposure, e.g., veterinarians, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis. The official preparation is human diploid cell vaccine produced from rabies virus grown in cultures of human diploid embryo lung cells and inactivated with propriolactone. It has a much lower incidence of adverse reactions than the previously used duck embryo vaccine. (12 Dec 1998) |
| vaccine | <pharmacology> A suspension of attenuated or killed microorganisms (bacteria, viruses or rickettsiae), administered for the prevention, amelioration or treatment of infectious diseases. Origin: L. Vaccinus (18 Nov 1997) |
| vaccine bodies | Old term pertaining to intracellular body's that were erroneously thought to be forms in the life cycle of a protozoan organism, Cytorrhyctes vaccinae, postulated to be the causal agent of vaccinia. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|